Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30756644 | 0.90 | PIM1 (0.43) | XDHKDM4CPIM1PIM2MAP4K4 | |
| SCHEMBL32667253 | 0.88 | MAP4K4 (0.48) | XDHIRAK4PIM1PIM2MAP4K4 | |
| SCHEMBL22262261 | 0.88 | OPRK1 (0.47) | XDHSCN9AIRAK4GRM4BRD4 | |
| SCHEMBL32667108 | 0.86 | IRAK4 (0.39) | XDHIRAK4PIM1PIM2MAP4K4 | |
| SCHEMBL32667179 | 0.83 | PRKAB2 (0.40) | XDHSCN9AIRAK4 | |
| SCHEMBL30756207 | 0.78 | TSHR (0.35) | XDHSCN9APIM1PIM2MAP4K4 | |
| SCHEMBL2488718 | 0.76 | SYK (0.41) | XDHKDM4CPIM1PIM2MAP4K4 | |
| SCHEMBL22262263 | 0.76 | XDH (0.44) | XDHSCN9AIRAK4PIM1PIM2 | |
| SCHEMBL17835490 | 0.75 | XDH (0.48) | XDHSCN9AKDM4CIRAK4PIM1 | |
| SCHEMBL20476485 | 0.75 | ALDH1A1 (0.50) | XDHPTGER1DHFRDCPSBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-07-26 | — | — | US | disclosed |
| CN-111094267-B | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3689860-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111094267-A | Sulfonyl-substituted bicyclic compounds as ROR gamma inhibitors | 正大天晴药业集团股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239454-A1 | SULFONYL SUBSTITUTED BICYCLIC COMPOUND WHICH ACTS AS ROR INHIBITOR | RORC, RORA, RORB | XDH 2362/4885SCN9A 1144/4885KDM4C 2173/4885 |
| US-11396503-B2 | Sulfonyl substituted bicyclic compound which acts as ROR inhibitor | RORC, RORA, RORB | XDH 2362/4885SCN9A 1144/4885KDM4C 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.